Merck KGaA has announced that the Phase IIIb SPARK study of Kuvan (sapropterin dihydrochloride) added to a phenylalanine-restricted diet in...
Merck Serono has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a...
Merck KGaA/Merck Serono has announced that the European Commission (EC) has authorized a change to the European marketing authorization for...
BioMarin Pharmaceutical has announced that it has acquired all global rights to Kuvan (sapropterin dihydrochloride) and pegvaliase from Merck Serono....